RGA Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

Operating EPS: $7.75 per share, marking the second consecutive record quarter.
Adjusted Operating Return on Equity (ROE): 15.7% for the trailing 12 months, exceeding the target range of 13% to 15%.
Full Year 2025 Performance: Record operating EPS, 15.7% ROE, and an 18% increase in the value of in-force business margins.
Capital Deployment: $2.5 billion into in-force transactions for the year; $98 million in Q4.
Share Repurchases: $50 million in Q4, totaling $125 million since reinstating buybacks in Q3 2025.
Excess Capital: $2.7 billion at the end of Q4, with deployable capital of $3.4 billion for the next 12 months.

2. Strategic Updates and Business Highlights

Regional Performance: Strong results across the U.S., EMEA, and APAC, with particular strength in individual life mortality and favorable experience in EMEA.
Balance Sheet Optimization: Continued management actions improved current earnings and ROE, enhancing future value and liability risk profile.
Investment Performance: Benefited from favorable variable investment income from alternative investments.
New Business Contributions: Ongoing success from recent business additions, including the Equitable block, which is expected to generate $160 million to $170 million in earnings for 2026.

3. Forward Guidance and Outlook

2026 Expectations: Anticipating a tax rate of 22% to 23% and projecting a variable investment income return of 7%.
EPS Growth Target: Reiterating an 8% to 10% annual EPS growth target, with a base case run rate EPS for 2025 at approximately $24.75.
In-Force Management Actions: Expected to have a more limited financial impact compared to recent years, with a projected capital deployment of around $1.5 billion in 2026.

4. Bad News, Challenges, or Points of Concern

U.S. Group Health Business: Experienced unfavorable claims experience, particularly in the excess medical business, leading to a decision to exit the group health care lines of business after 2026.
Economic Claims Experience: Unfavorable by $51 million in Q4, with a significant portion attributed to the U.S. group business.
Market Competition: Increased competition in the EMEA region due to regulatory changes that may allow competitors to be more aggressive in pricing.

5. Notable Q&A Insights

Capital Allocation: Management confirmed the continued target of a 20% to 30% payout ratio for buybacks and dividends, with flexibility to adjust based on opportunities.
Equitable Block Performance: Clarified that the performance discrepancies between RGA and Equitable are due to different reserving assumptions and operational efficiencies.
Long-Term Care (LTC) Business: Management expressed satisfaction with their LTC business performance, emphasizing a disciplined approach to managing exposure.
Investment Portfolio: Minimal exposure to software-related companies, with a strong focus on managing risks associated with AI disruptions.

Overall, RGA reported strong financial results for Q4 2025, driven by effective capital deployment and strategic management actions, while navigating challenges in specific business segments and market competition. The company remains optimistic about future growth and strategic positioning.

RGA — Reinsurance Group of America, Incorporated